Background-Diabetic cardiomyopathy is characterized by energetic dysregulation caused by glucotoxicity, lipotoxicity, and mitochondrial alterations. p53 and its downstream mitochondrial assembly protein, synthesis of cytochrome c oxidase 2 (SCO2), are important regulators of mitochondrial respiration, whereas the involvement in diabetic cardiomyopathy remains to be determined. Methods and Results-The role of p53 and SCO2 in energy metabolism was examined in both type I (streptozotocin [STZ] administration) and type II diabetic (db/db) mice. Cardiac expressions of p53 and SCO2 in 4-week STZ diabetic mice were upregulated (185% and 152% versus controls, respectively, PϽ0.01), with a marked decrease in cardiac performance. Mitochondrial oxygen consumption was increased (136% versus control, PϽ0.01) in parallel with augmentation of mitochondrial cytochrome c oxidase (complex IV) activity. Reactive oxygen species (ROS)-damaged myocytes and lipid accumulation were increased in association with membrane-localization of fatty acid translocase protein FAT/CD36. Antioxidant tempol reduced the increased expressions of p53 and SCO2 in STZ-diabetic hearts and normalized alterations in mitochondrial oxygen consumption, lipid accumulation, and cardiac dysfunction. Similar results were observed in db/db mice, whereas in p53-deficient or SCO2-deficient diabetic mice, the cardiac and metabolic abnormalities were prevented. Overexpression of SCO2 in cardiac myocytes increased mitochondrial ROS and fatty acid accumulation, whereas knockdown of SCO2 ameliorated them.
D iabetic cardiomyopathy is one of the leading causes of increased morbidity and mortality in the patients with diabetes mellitus. 1, 2 Although the pathogenesis of this cardiac contractile dysfunction is still unclear, an involvement of increased reactive oxygen species (ROS) production 3 and altered mitochondrial function 4, 5 have been reported. Mitochondrial uncoupling was shown to be a possible mechanism to reduce cardiac efficiency in type 2 diabetes models 6 but not in type 1 diabetes models. 7 Recent study using positron emission tomography in patients with type 1 diabetes mellitus has revealed the Clinical Perspective on p 115 increased oxygen consumption and altered fatty acid (FA) metabolism. 8 These human and animal studies have shown that increased oxidative stress correlates with lipid overload, suggesting a role for FA in the generation of ROS, 7, 8 whereas an involvement of ROS generated by high glucose concentrations in metabolic abnormalities in diabetic cardiomyopathy remains to be determined. 7 Tumor suppressor, p53, has a well-characterized role in regulating apoptosis and the cell cycle in response to genomic stress; however, its broader roles in organ homeostasis are just beginning to be understood. 9 Especially, activation of p53 protein demonstrated critical roles in the heart. Induction of p53 protein by myocardial ischemia is associated with decreased survival rate due to cardiac rupture. 10 Doxorubicin induced the expression of p53 and cardiac toxicity associated with myocyte apoptosis. 11 Chronic pressure overload upregulated p53 protein to cause inhibition of Hif-1 activity, which impaired cardiac angiogenesis and contractility. 12 We previously reported that p53 regulates mitochondrial respiration (oxygen consumption), 13 in which we newly discovered the synthesis of cytochrome c oxidase 2 (SCO2) as a novel transcriptional target of p53 and demonstrated that p53 positively regulated mitochondrial respiration through SCO2 expression. Rescue of SCO2 in p53-deficient cells restored the impaired aerobic respiration, indicating that p53 directly regulates mitochondrial respiration through SCO2. 13 The SCO2 protein is essential for the assembly of mitochondrial cytochrome c oxidase (complex IV), the metabolic center of oxygen consumption. 14 Although the biological significance of the p53/SCO2 pathway remains to be clarified, p53-mediated regulation of mitochondrial respiration might suggest a new mechanism in cardiac metabolic alterations.
In the present study, we focused on the role of the cardiac p53/SCO2 system in mitochondrial respiration, lipid metabolism, and cardiac performance in the diabetic hearts. Our results demonstrate for the first time that SCO2 plays a crucial role in the enhancement of mitochondria-derived ROS generation and lipid accumulation by increasing mitochondrial respiration, suggesting a novel function of p53 and the SCO2 system in regulating cardiac energy metabolism in the diabetic hearts.
Methods

Animals
All animals were handled in accordance with the Guidelines for the Care and Use of Laboratory Animals published by the US National Institutes of Health. The protocol was approved by the bioethics committee of Kyoto Prefectural University School of Medicine.
Each method is described in the online-only Data Supplement material.
Statistical Analysis
Data were expressed as meanϮSEM. For comparison of variables of the excised hearts in the same gene model, a 1-way ANOVA test was performed. Then Bonferroni procedure was used to assess differences between individual groups. To assess group differences over time or intervention, 2-way ANOVA was used. We verified that the data were normally distributed and used parametric tests. After finding significant interaction among the data in each group and time point, differences were assessed with the Bonferroni procedure. Data between 2 groups were compared using the unpaired t test. A probability value of Ͻ0.05 was considered to indicate statistical significance.
Results p53 Expression Is Upregulated in Diabetic Hearts to Cause Impairment of Cardiac Function
To investigate the role of p53 in the diabetic heart, wild-type p53 (ϩ/ϩ) and p53 (Ϫ/Ϫ) mice were treated with STZ (type 1 diabetes mellitus model). p53 protein expression was increased 4 and 8 weeks after injection of STZ (188% and 152% versus control, respectively, PϽ0.01; Figure 1A ). Left ventricular fractional shortening was significantly decreased in p53 (ϩ/ϩ) mice (75.8% at 4 weeks and 67.7% at 8 weeks versus baseline), whereas these alterations were not observed in p53 (Ϫ/Ϫ) mice (95.1% at 4 weeks and 91.9% at 8 weeks versus baseline; Figure 1B and 1C and online-only Data Supplement Table 1 ). There were no significant differences in glucose and lipid profiles after STZ injection between p53 (ϩ/ϩ) and p53 (Ϫ/Ϫ) mice (online-only Data Supplement Figure 1A and 1B). BNP mRNA levels were upregulated significantly 4 and 8 weeks after STZ injection in p53 (ϩ/ϩ) diabetic heart (3.1-and 3.5-fold versus baseline), whereas there were no significant changes in p53 (Ϫ/Ϫ) mice (onlineonly Data Supplement Figure 1C ).
ROS-Mediated DNA Damage and Lipid Accumulation Are Decreased in p53 (؊/؊) Diabetic Hearts
To study the effect of p53 deficiency on diabetic hearts, we performed histological examination of the left ventricle (interstitial fibrosis, vessel formation) at 4 weeks after STZ injection. Hematoxylin and eosin and Masson's trichrome staining showed that there were no significant changes in myocyte size, infiltration of inflammatory cells, interstitial fibrosis, and the numbers of CD31-positive cells between p53 (ϩ/ϩ) and p53 (Ϫ/Ϫ) diabetes mice (online-only Data Supplement Figure 2A through 2C). Although TUNELpositive cells were increased 3, 7, and 14 days after STZ injection, their numbers were not significantly different between p53 (ϩ/ϩ) and p53 (Ϫ/Ϫ) diabetes mice (onlineonly Data Supplement Figure 3 ). In contrast, we found marked increases in ROS-damaged DNA (8-OHdG immunostaining) and lipid accumulation (oil-red-O staining) in p53 (ϩ/ϩ) diabetic hearts, whereas these changes were barely observed in p53 (Ϫ/Ϫ) diabetic mice (Figure 2A through 2H).
Electron micrographs revealed that lipid droplets were more accumulated around mitochondria in myocytes from p53 (ϩ/ϩ) diabetic mice (3.4-fold versus control), whereas such change was not observed in p53 (Ϫ/Ϫ) diabetic mice ( Figure 2I through 2L). We also analyzed cardiac triglyceride and mitochondrial DNA contents. Triglyceride content was increased in p53 (ϩ/ϩ) diabetic hearts (2.3-fold versus control, PϽ0.01; Figure 2N ) but not in p53 (Ϫ/Ϫ) diabetic mice. Mitochondrial DNA content did not show any significant change between p53 (ϩ/ϩ) and p53 (Ϫ/Ϫ) mice ( Figure 2O ).
Mitochondrial Oxidative Respiration Is Augmented in Diabetic Heart
Because the increase of mitochondrial respiration and FA influx caused myocardial lipid accumulation, 6, 8, 15 we evaluated the functional change in mitochondrial oxidative
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respiration of diabetic hearts. Basal respiration (state 2, Vo), ADP-stimulated respiration (state 3, V ADP ), and oligomycin-administered respiration after ADP stimulation (state 4, Voligomycin) were compared in p53 (ϩ/ϩ) and p53 (Ϫ/Ϫ) mice. In the p53 (ϩ/ϩ) diabetic hearts, state 3 respiration (V ADP ) was significantly increased (136% versus control, PϽ0.01; Figure 3A ), whereas this change was not observed in p53 (Ϫ/Ϫ) diabetic mice ( Figure 3A ). There were no alterations in state 2 (Vo) or state 4 (Voligomycin) respirations in p53 (ϩ/ϩ) and p53 (Ϫ/Ϫ) diabetic hearts ( Figure 3A ). Considering that the state 4 respiration was reported to reflect uncoupling of mitochondrial oxidative phosphorylation, 6, 16 the present findings raised the possibility that mitochondrial uncoupling was not involved in STZinduced diabetic hearts. We also analyzed the individual activity of mitochondrial complexes I-IV, composing the mitochondrial electron transport chain. Normally, mitochondria respiration generates a proton gradient by transferring electron through complexes I, III, and IV. Alteration in each complex activity is an important functional clue to clarify diabetes-mediated mitochondrial abnormalities. The result showed that the increase in oxygen consumption in p53 (ϩ/ϩ) diabetic mice was mainly due to the augmentation of mitochondrial complex IV activity (135% versus control, PϽ0.01; Figure 3B ). As the mitochondrial complex IV, a final electron acceptor in this chain, has the greatest capacity of oxygen consumption, these data indicated that the elevated activity of mitochondrial complex IV is responsible for the abnormalities of mitochondrial function in the diabetic hearts.
To further examine the time-dependent changes of mitochondrial respiration, we measured mitochondrial complex activities at 0, 2, 4, and 8 weeks after STZ injection. Mitochondrial complex IV activity was significantly augmented in p53 (ϩ/ϩ) diabetic heart at 4 and 8 weeks after STZ injection (135% and 132% versus control, respectively, PϽ0.01), whereas the activity was not changed in p53 (Ϫ/Ϫ) diabetic mice, and mitochondrial complex I-III activities were not affected during 8 weeks in both p53 (ϩ/ϩ) and p53 (Ϫ/Ϫ) diabetic hearts ( Figure 3C and 3D). We next analyzed whether p53 induction and the increase of mitochondrial respiration are dependent on diabetes. By treating STZ-induced diabetic mice with insulin for 4 weeks (0.2 U insulin/day), the glucose levels were decreased to the control range (238Ϯ56 mg/dL at 4 weeks, nϭ6) and the upregulation of state 3 respiration, complex I-IV activities, and induction of p53 were all reversed to the control levels. Insulin treatment also improved cardiac dysfunction and lipid accumulation (online-only Data Supplement Figure 4 ). 
SCO2 Is Induced in Diabetic Hearts to Augment FA Metabolism and Uptake
SCO2 protein is essential for the assembly of the mitochondrial complex IV and is transcriptionally regulated by p53. We studied SCO2 expression in STZ-induced diabetic hearts. The expression of SCO2 was markedly increased 4 and 8 weeks after STZ injection (148% versus control, respectively, PϽ0.01) in p53 (ϩ/ϩ) diabetic mice, whereas there was no significant difference in p53 (Ϫ/Ϫ) diabetic mice ( Figure 4A ).
We further examined SCO2-mediated FA metabolism by using SCO2-overexpression myocytes. Cardiac myocytes were incubated with 14 [C]-oleate, and the amounts of metabolized FA (assessed by 14 [C]O 2 production from 14 [C]-oleate) and amounts of 14 [C]-oleate residual in myocytes were then measured. As shown in Figure 4B , SCO2 overexpression induced an increase (1.3-fold versus control) in 14 [C]O 2 production from 14 [C]-oleate, whereas amounts of residual 14 [C]oleate further increased (1.5-fold versus control). Knockdown of SCO2 reduced 14 [C]O 2 production and amounts of residual 14 [C]-oleate ( Figure 4C ), and accumulation of fluorescent long-chain FA analog (BODIPY-conjugated palmitate) was also augmented by SCO2 induction ( Figure 4D ). These findings suggest that p53/SCO2 drives increased lipid accumulation in the context of increased oleate oxidation.
SCO2 overexpression caused a marked increase in mitochondrial ROS generation assessed by MitoSox fluorescence (1.4-fold versus control, Figure 4E ). Mitochondria were visualized with Mitotracker. Image merging of MitoSox with Mitotracker showed that the enhanced ROS was generated from mitochondria ( Figure 4F ), suggesting that SCO2 stimulates the uptake and utilization of FA and augments mitochondrial ROS generation in cardiac myocytes.
Tempol Treatment Improves Cardiac and Metabolic Dysfunction
To investigate the implication of oxidative stress in STZinduced diabetes mice, we examined the effect of tempol for 35 days, since 7days before STZ injection. As shown in online-only Data Supplement Figure 5A , tempol pretreatment normalized the elevated p53 and SCO2 protein levels on day 28. Augmented consumption of mitochondrial oxygen and ROS-mediated DNA damage were reduced by tempol (online-only Data Supplement Figure 5B and 5C). Cardiac dysfunction and BNP levels were improved toward normal levels (online-only Data Supplement Figure 5D and 5E).
To examine the effect of ROS on the myocyte contraction and viability, we compared contraction rates of pulsestimulated myocytes after administration of oleate. We found that oleate stimulated ROS generation in myocytes (online-only Data Supplement Figure 6A ), and oleateinduced ROS reduced myocyte contraction (45% versus control, PϽ0.01) without a significant change in cell viability or apoptotic cell number (online-only Data Supplement Figure 6B through 6D).
SCO2 (؉/؊) Diabetic Mice Reproduce the Metabolic Phenotype of p53 (؊/؊) Diabetic Mice
Because SCO2 (Ϫ/Ϫ) mice were embryonically lethal, 17 we studied the role of SCO2 using SCO2 (ϩ/Ϫ) mice. The basal level of SCO2 protein was lower (32% versus control, PϽ0.01) in SCO2 (ϩ/Ϫ) hearts compared with SCO2 (ϩ/ϩ) hearts ( Figure 5A ). After administration of STZ, the level of SCO2 was increased in diabetic SCO2 (ϩ/ϩ) hearts (151% versus control, PϽ0.01) but not in diabetic SCO2 (ϩ/Ϫ) hearts ( Figure 5A ). Although blood glucose and lipid profile were significantly increased in diabetic SCO2 (ϩ/Ϫ) mice (online-only Data Supplement Figure 7A ), no apparent difference in the histological analyses (hematoxylin and eosin and Masson's trichrome staining) was observed between control and diabetic SCO2 (ϩ/Ϫ) mice (online-only Data Supplement Figure 7B ). Basal mitochondrial complex IV activity was significantly decreased (64% versus control, respectively, PϽ0.01) in SCO2 (ϩ/Ϫ) hearts compared with SCO2 (ϩ/ϩ) hearts ( Figure 5B ). Although complex IV activity was increased in diabetic SCO2 (ϩ/ϩ) hearts (135% versus control, respectively, PϽ0.05), there was no significant increase in diabetic SCO2 (ϩ/Ϫ) hearts ( Figure 5B ). No apparent changes were observed in ROS damage, lipid accumulation and lipid droplet in the myocardium of SCO2 (ϩ/Ϫ) mice ( Figure 5C ). Cardiac contractile function (%FS) and BNP mRNA levels did not significantly change in diabetic SCO2 (ϩ/Ϫ) mice ( Figure 5D and 5E and onlineonly Data Supplement Table 2 ). These findings indicated that diabetes-induced cardiac dysfunction resulted from SCO2-mediated excessive responses in mitochondrial respiration, ROS production and lipid accumulation.
Expression Profiles of Genes Regulating Cardiac FA Metabolism
We next examined the expressions of genes closely involved in cardiac FA metabolism. 5, 18, 19 Although peroxisome proliferator-activated receptor-␣ mR⌵〈 levels were unchanged (online-only Data Supplement Figure 8A ), the mRNA expression of proliferator-activated receptor-␥ coactivator 1 (PGC-1) ␣ was elevated to a similar extent in p53 (ϩ/ϩ) and p53 (Ϫ/Ϫ) diabetic hearts (174% and 159% versus control, PϽ0.05, online-only Data Supplement Figure  8B ). The mRNA expressions of FA import regulating genes, such as fatty-acid transport protein (FATP) and carnitine palmitoyltransferase I, did not differ between p53 (ϩ/ϩ) and p53 (Ϫ/Ϫ) diabetic hearts, whereas FAT/CD36 mRNA was significantly upregulated in p53 (ϩ/ϩ) diabetic mice (onlineonly Data Supplement Figure 8C through 8F).
FAT/CD36 Protein Is Localized at Membrane of Myocytes
FA enter myocytes by passive diffusion or by protein carriermediated pathway. 20 This mechanism for protein-mediated uptake involves binding of FA to FA-binding protein (FABP), which concentrates the FA by either passive diffusion or uptake through the FAT/CD36-or FATP1-mediated pathway. 21 FAT/CD36 translocates between intracellular endosomes and sarcolemmal membrane, known to be important in the regulatory control of fatty acid uptake. 22 Therefore, we examined membrane localization of FA transporter, FAT/ CD36 protein, and FATP1 protein. Caveolin 3 was used as a sarcolemmal marker. The expression of FATP1 protein was not altered in diabetic p53 (ϩ/ϩ) mice (data not shown). Cardiac expression of sarcolemmal FAT/CD36 was significantly increased in diabetic p53 (ϩ/ϩ) mice (151% versus Figure 9A ).
We also examined the regulation of FAT/CD36 in cardiac myocytes. p53 induction by nongenotoxic p53 activator Nutlin-3 upregulated FAT/CD36 mRNA expression in a time-dependent manner (online-only Data Supplement Figure  9B ). Induction of p53 augmented CD36 expression (onlineonly Data Supplement Figure 9C ). Treatment with antioxidant tempol reduced the induction of FAT/CD36 protein (online-only Data Supplement Figure 9C ). Administration of H 2 O 2 (1ϫ10 Ϫ8 mol/L) induced CD36 expression with p53 protein, and knockdown of p53 inhibited CD36 expression (online-only Data Supplement Figure 9D ). Knockdown of CD36 gene downregulated the basal expression of CD36 mRNA to the control level and inhibited nongenotoxic p53 activator Nutlin-3-mediated residual oleate to the control level (online-only Data Supplement Figure 9E ), whereas overexpression of SCO2 markedly induced FAT/CD36 protein expression (2.8Ϯ0.6-fold versus control, online-only Data Supplement Figure 10A ).
p53/SCO2 Expression and Lipotoxicity Are Involved in db/db Mouse Heart
We also examined whether the induction of p53/SCO2 protein and mitochondrial function in STZ-treated mice was similarly observed in the genetic model of type 2 diabetes. Ten-week-old db/db mice showed hyperglycemia and lipid profile abnormality (online-only Data Supplement Figure  11A ). We found that cardiac contractile function was impaired (63% versus db/ϩ, PϽ0.01; online-only Data Supplement Figure 11B and online-only Data Supplement Table 3 ) and cardiac p53 and SCO2 expressions were increased in db/db mice (208% and 151% versus db/ϩ, PϽ0.01; onlineonly Data Supplement Figure 11C ). Along with the increase in SCO2 expression, state 3 respiration (V ADP ), oxygen consumption, and mitochondrial complex IV activity were upregulated in db/db hearts (156%, 142%, and 131% versus db/ϩ; online-only Data Supplement Figure 11D ). Moreover, ROS-mediated DNA damage (8OHdG) and lipid accumulation (oil-red-O) were apparently increased in db/db hearts compared with db/ϩ hearts (online-only Data Supplement Figure 11E ). A, At baseline, SCO2 protein expression in the heart was less in SCO2 (ϩ/Ϫ) mice than SCO2 (ϩ/ϩ) mice. SCO2 protein was induced after the injection of streptozotocin (STZ) in SCO2 (ϩ/ϩ) mice. B, Mitochondrial complex IV activity was less in SCO2 (ϩ/Ϫ) mice than that in SCO2 (ϩ/ϩ) mice and was not induced in SCO2 (ϩ/Ϫ) diabetic mice. C, Reactive oxygen species (ROS)-induced DNA damage, lipid accumulation, and lipid droplets (arrowheads) were not increased in SCO2 (ϩ/Ϫ) diabetic mice. D, Contractile function was preserved in SCO2 (ϩ/Ϫ) diabetic mice. E, BNP mRNA levels were increased in SCO2 (ϩ/ϩ) diabetic mice, whereas there was no increase in SCO2 (ϩ/Ϫ) diabetic mice (nϭ12 each). **PϽ0.01 versus SCO2(ϩ/ϩ) control; #PϽ0.05 versus SCO2 (ϩ/ϩ) control.
Electron micrographic analysis showed that the number of lipid droplets around mitochondria was increased in cardiac myocytes from db/db mice compared with db/ϩ mice (4.9fold versus control; online-only Data Supplement Figure  11E ). Thus, cardiac lipotoxicity was observed in db/db mice, in which the expressions of p53 and SCO2 were markedly induced as observed in STZ-induced diabetic mice.
Discussion
We have previously reported that p53 regulates mitochondrial respiration through activation of SCO2, a transcriptional target of p53. 13 The present study is the first to focus on the role p53/SCO2 on energy metabolism in the diabetic hearts; we found that (1) the expressions of p53 and SCO2 were induced with the progression of cardiac dysfunction in type 1 and type 2 diabetic mice in a ROS-dependent manner; (2) activated SCO2 enhanced the mitochondrial complex IV activity and upregulated the rate of FA oxidation and excessive generation of mitochondria-derived ROS, resulting in the lipid accumulation and DNA damage in myocytes. Inhibition of SCO2 function suppressed the augmentation of mitochondrial respiration and protected heart against the progression of diabetic cardiomyopathy; and (3) induction and translocation of FA translocase FAT/CD36 were highly associated with activation of the p53/SCO2 system, resulting in lipid overstorage in myocytes. These findings suggest that lipotoxicity with excessive augmentation of mitochondrial respiration through the p53/SCO2 system plays an important role in the progression of diabetic cardiomyopathy.
In diabetic hearts, energy production derived from FA oxidation is promoted despite the decrease in energy production from glucose oxidation. 23 This alteration is accompanied with increased myocardial oxygen consumption. Because cardiac work is unchanged or reduced, energy efficiency is relatively declined in diabetic animal and human hearts. 24, 25 Tumor suppressor, p53, has a well-characterized role in regulating apoptosis and cell cycle in response to genomic stress; however, its role on metabolism remains to be determined. 9 In cardiac myocytes, p53 is activated by high glucose, leading to myocyte death. 26 In the in vivo condition, hyperglycemia causes enzymatic O-glycosylation of p53, whose activation enhances myocyte apoptosis. 27 Our present findings demonstrated that diabetic condition caused excessive oxidative DNA damage with p53 induction, and this change was inhibited by administration of antioxidant ( Figure  1A and online-only Data Supplement Figure 5 ), suggesting that diabetes-induced ROS generation upregulates the expression of p53, and the p53 increases mitochondrial respiration through the p53 downstream mitochondrial assembly protein, SCO2.
It remains to be determined how diabetes-mediated increase in oxygen consumption is associated with cardiac dysfunction. SCO2 overexpression augments oxygen consumption, 13 and higher respiration activity generates more ROS. 28 Oxidative stress and p53 have been suggested by several studies to underlie hyperglycemia-induced myocardial cell death. 26, 29, 30 Despite its prime importance of cell death, mitochondrial alteration by ROS was reported to cause cardiomyocyte damages in STZ-induced diabetic mice and db/db mice. 7 As shown in online-only Data Supplement Figure 3 , there was no significant difference in apoptotic cell numbers between p53(ϩ/ϩ) and p53(Ϫ/Ϫ) mice, although the numbers tended to be decreased in p53(Ϫ/Ϫ) mice. Thus, as the present result indicated that the reduced contractile performance in the diabetic hearts probably was not due to cell death and loss of parenchymal cells from the organ, we next examined whether generation of ROS actually affects contraction activities of myocytes in vitro and found that oleate-induced ROS markedly reduced myocyte contraction rates (45% versus, control, PϽ0.01) without a change in cell viability or apoptotic cell numbers (online-only Data Supplement Figure 6 ). Taken together with the result that antioxidant tempol inhibited the upregulation of p53 and SCO2 and improved cardiac dysfunction in diabetic p53 (ϩ/ϩ) mice to the level similar to p53 (Ϫ/Ϫ) mice (Figure 1 and online-only Data Supplement Figure 5 ), these findings suggest that reduced cardiac function in the diabetic hearts is due to ROS-mediated, direct inhibitory effects on contractile performance of individual myocytes rather than loss of parenchymal cells from the organ. SCO2 protein is essential for the assembly of complex IV, the metabolic center of eukaryotic oxygen consumption. Disruption of SCO2 eliminates mitochondrial respiration, 31 and overexpression of SCO2 augments mitochondrial respiration. 13 We showed, using SCO2 (ϩ/Ϫ) mice, the marked decreases in SCO2 expression and mitochondrial respiration compared with the wild-type mice ( Figure 5 ). In the STZinduced diabetic conditions, myocardial oxygen consumption was increased as much as 36% (Figure 3 ), and SCO2 expression was also markedly induced (148% versus control) ( Figure 4 ). These alterations were also observed in db/db mice (online-only Data Supplement Figure 11 ), indicating the critical involvement of p53 and SCO2 in the increase of mitochondrial respiration in diabetic hearts. In the present study, we found for the first time that p53/SCO2 increased mitochondrial respiration activity to cause the uptake lipid more than its necessary consumption rate, thus leading to the lipid overstorage and ROS production. We also showed that increased CD36 expression in the membrane of myocytes was closely associated with p53, and knockdown of CD36 inhibited p53-mediated oleate uptake to the control level (online-only Data Supplement Figure 9 ). Loss-of-function studies using CD36-deficient mice would be necessary to further define the role of FA transporter and lipotoxicity in the diabetic heart. Considering that there are p53 consensus binding sites in the promoter regions of human and rat/mouse CD36 genes (online-only Data Supplement Figure 10B) , it might be possible to speculate that the expression of the CD36 gene is transcriptionally regulated by p53. Further studies, such as luciferase assays or chromatin-p53 immunoprecipitation experiments, will be needed to define the p53-mediated transcriptional control of CD36 gene.
PGC-1␣ is a pivotal mediator of energy metabolism in augmenting lipid metabolism and mitochondrial biogenesis. 5, 19 In the insulin-resistant diabetic heart, PGC-1␣ was activated and PGC-1␣-mediated mitochondrial biogenesis is assumed as an adaptive response to increased FA oxidation. 5 Sahin et al reported that p53 also represses PGC-1␣ and damages heart mitochondria in the setting of telomere dysfunction. 19 They described that p53 can exert varied effects in other physiological settings, citing our previous results. 13 In our diabetic mice, PGC-1 ␣ was upregulated independent of p53 status (online-only Data Supplement Figure 8B ). In contrast to the previous results by the DePinho group, p53 did not exert a repressive effect on PGC-1␣. As p53 is a multifunctional protein important for the maintenance of genomic integrity, timing and duration of p53 activation affects the number of its downstream genes. Modulation of PGC-1␣ might be a potential avenue to protect the heart from the development of diabetic cardiac dysfunction. Senile diabetic mice models or longer exposure to high glucose of the heart might reveal another role of p53 and PGC-1␣.
In conclusion, we found for the first time that diabetesinduced ROS generation upregulates p53 and SCO2, resulting in the increase of mitochondrial respiration and subsequent lipid accumulation and excessive generation of mitochondrial ROS. This hypothesis was supported in our in vitro study showing that SCO2-overexpressing myocytes accelerated lipid uptake and mitochondrial ROS generation in substraterich circumstances, and knockdown of SCO2 reduced FA metabolism. Thus, p53 and SCO2 may be therapeutic targets to prevent the progression of diabetes-mediated cardiac dysfunction.
